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Biotechnology--with a heavy emphasis on both 
'bio' and 'technology' 
Biotechnology has continued to advance the state of 
the art in pharmaceutical research and discovery, es- 
pecially in the generation and screening of molecu- 
lar diversity [1]. Patents have begun to issue on both 
chemical [2] and biological [3] strategies for creating 
and evaluating libraries of compounds. Whether struc- 
tured or random in design, these combinatorial col- 
lections, composed of natural and/or unnatural build- 
ing blocks, are transforming the face of 'lead' discov- 
ery and optimization. Surely, the original 'mimotope' 
strategies of roughly a decade ago will soon yield 
to true paradigms of molecular evolution. Of course, 
discovery is only one stage of pharmaceutical R & D, 
and few groups have adequately addressed important 
early development parameters such as absorption (for 
oral delivery), distribution, metabolism, and elimina- 
tion. Nevertheless, with more compounds having been 
made and tested in the 1990s than in the combined 
history of the pharmaceutical industry before 1990, 
we are witnessing a literal flood of new compounds 
and biological data not unlike that presenting itself to 
the various genome projects. In fact, common bioinfor- 
matics solutions may pertain to modern combinatorial 
drug screening and genome data capture, analysis, and 
database problems. 
On to development and commercialization 
In the wake of significant disappointments surround- 
ing potential monoclonal antibody (mAb) therapies 
for septic shock, it is gratifying to recognize the suc- 
cess of interleukins (ILs), interferons (IFNs), and other 
immunomodulators in certain infectious and inflamma- 
tory diseases. While not always without controversy, 
biotechnology produced enzymes are also proving ef- 
ficacious: tissue plasminogen activator (tPA; alteplase) 
for dissolving clots; alglucerase for Gaucher's disease; 
and dornase et (DNase) for cystic fibrosis. The impor- 
tance of the immune system in all of these strategies is 
becoming ever more clear. 
If only we could forget 
Notwithstanding the history of septic shock, or the dif- 
ficulties intrinsic to therapeutic approaches for critical 
care and resulting multiple organ system failure, the fu- 
ture will surely bring more positive results. Russell and 
Thompson (pp 714-721) summarize the major biotech- 
nology approaches to treating septic shock, discussing 
the 'yin and yang' of tumor necrosis factor (TNF)-c~ 
and IL-1]] strategies. The jury is still out on which, if 
either, will win. Indeed, alternative or combination ap- 
proaches focusing on different antibodies, tissue fac- 
tors, antioxidants, complement inhibitors, metabolic 
mediators, etc may ultimately prove critical to more 
effective therapeutics. 
The promise 
Certain biotech products may eventually find greater 
use outside their original applications. Human growth 
hormone is an example of a protein with signif- 
icant off-label use and potential. Aldesleukin IL-2 
mutein is an example of a biotechnology product ap- 
proved for a very specifc indication, metastatic re- 
nal cell carcinoma, but with potentially far greater 
utility in infectious disease. Giedlin and Zimmerman 
(pp 722-726) summarize recent insights into the role 
of IL-2 and T-helper cells in the control of infectious 
disease. Schreurs (pp 727-733) extends the discussion 
to macrophage-inactivating cytokines such as trans- 
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forming growth factor (TGF)-[3, IL-10, and cytokines 
that activate the inmmne system, including TNF-~ and 
IFN-T. 
Virulence 
Recent efforts to identify and characterize virulence fac- 
tors in pathogenic bacteria using innovative molecular 
approaches represent an exciting area of research in 
which basic science has merged with the most modern 
biotechnology methods [4,5]. Given the importance of 
this work, and the fact that it is not covered elsewhere 
in this issue, we comment in more detail on this area 
in the following section. 
Initial work concerning virulence was based on two 
assumptions: the notion that virulence factors in a 
particular pathogen are coordinately expressed and, 
thus, controlled by the same regulatory system; and 
that virulence factors are often secreted or surface- 
exposed proteins that interact with host factors in a 
direct manner. Following the isolation and study of a 
virulence determinant whose expression can be eas- 
ily monitored (e.g. a toxin or a hemolysin), it becomes 
possible to identify other genes or gene products ex- 
pressed under the same conditions, without knowing 
much at the start about what these factors might be. 
This can be accomplished either by assaying total pro- 
tein profiles in two dimensions after growth under  spe- 
cific in vitro or in vivo conditions, or by making ran- 
dora gene fusions using transposable elements. The lat- 
ter method employs a modified transposon to deliver 
a reporter gene lacking its own regulatory elements. 
Once the reporter gene has been fused to a gene of 
interest, reporter expression reflects that of the gene 
into which it has been  transposed. 
With the development  of the specialized transposon 
TnphoA, which allows investigators to target gene fu- 
sions specifically to genes encoding secreted proteins, 
a convergence of the principles of coordinate regu- 
lation and gene fusion has become possible. Thus, 
Mekalanos and colleagues were able to identify a viru- 
lence regulon (comprising more than 15 genes) in Vib- 
rio cholerae by using TnphoA to identify genes whose 
expression was coordinately controlled by a single reg- 
ulatory element. More recently, an elegant refinement 
of this approach has been the development  of  random 
gene fusion technology to screen for promoters that 
are specifically expressed by microbes during infec- 
tion. This method is based on the assumption that it 
might not be possible to identify genes in vitro that 
are expressed, or optimally expressed, only in vivo. 
In this approach, a transposon is engineered with a 
gene encoding an essential function for Salmonella 
typhimurium growth in vivo. The gene purA lacks 
its own promoter but is expressed when transposed 
downstream from an active promoter. A population 
of S. typhimurium purA nmtants, in which transpo- 
sition of the engineered purA gene is allowed to oc- 
cur, is passaged through mice. Survival of  any particu- 
lar cell is dependent  on having purA expressed from a 
promoter active during the course of infection. In this 
fashion, several genes whose  expression is specifically 
identified during in vivo growth can be identified and 
isolated. This represents an important conceptual ad- 
vance in our ability to probe the pathophysiology of 
infectious diseases, and perhaps to identify agents that 
may intervene at specific and critical steps that are part 
of the in vivo lifecycle of a pathogen. 
Back to the future by learning from the past 
Growth hormones and colony stimulating factors 
(CSFs) have a checkered history in the biotechnol- 
ogy industry. They include the remarkable successes 
of CSFs like filgrastim (G-CSF) and sargramostim (GM- 
CSF), epoetin et, and growth hormone (somatropin; so- 
matrem), and the less conclusive results (thus far) with 
growth factors such as the neurotrophins [e.g. nerve 
growth factor (NGF)]. Ultimately, the pleitropic actions 
of the many growth factors currently under  study will 
be harnessed to the desired ends, but probably not 
this year. This is unfortunate, for perhaps the area with 
greatest untapped potential as a target for biotechnol- 
ogy products is the brain; nonetheless, delivery across 
the blood-brain barrier (BBB) and specificity to periph- 
eral compartments become major issues biasing many 
laboratories toward small molecules. 
It has been difficult to study and characterize the mech- 
anism for transfer of therapeutic compounds across the 
BBB. Because of the anatomy of the BBB, the devel- 
opment of cell-based models that relate appropriately 
to the in vivo transfer of drug candidates into the CNS 
has been problematic. Many CNS drugs cross the BBB 
via the phospholipid membranes of endothelial cells. 
To accomplish this task, however, a drug nmst travel 
from one aqueous compartment into a lipid mem- 
brane and back into another aqueous compartment 
several times. Osmotic shock can be used to open 
the BBB, but its non-selective action allows both de- 
sired and undesired substances to enter. Of course, ac- 
tive and passive transport mechanisms exist for both 
small molecules and macromolecules such as proteins. 
Receptor-mediated uptake (e.g. hormone receptor en- 
docytosis) is a well known phenomenon  that has yet 
to be truly exploited in this respect. Antibody conju- 
gates, polymer encapsulation, and adenovirus vectors 
represent new approaches to delivery. Reynolds and 
Weiss (pp 734-738) provide an up-to-date assessment 
of the untapped potential of growth factors in CNS ther- 
apies, with a representative cross-section of  this field. 
While CNS targeting is still more of a promise than a 
reality, the targeted delivery of immunotoxins, and the 
like, has much more experience to draw from. Hous- 
ton (pp 739-744) provides a sobering look at the the 
experience, to date, in cancer (among other diseases) 
and reviews the problems and opportunities. 
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Last, but certainly not least 
Inflammatory processes are currently implicated in 
arthritis, cancer, infectious disease, Alzheimer's disease, 
and everything in between. The inmmnology commu- 
nity has finally hit on the hottest of targets--cell-adhe- 
sion molecules (CAMs). The explosion of publications 
and patents in the CAM arena is staggering. These 
multiple gene families (integrins, selectins, etc) pro- 
vide a wealth of new targets for immunologists and 
drag-hunters alike. Peltz (pp 745-750) gives a fresh 
perspective on this burgeoning field. 
Adolescence 
Maturation of the biotechnology industry has led to the 
recognition that only some products, when targeted 
to the appropriate patient population with convinc- 
ing efficacy, can reach marketplace with due speed. 
Other products have taken, or will take, the more tradi- 
tional pharmaceutical course of a decade or more, with 
R & D expenses in excess of $100 million. Perseverance 
in the biotechnology industry has, at times, spanned 
several companies and multiple partnerships. Fortu- 
nately, biotechnology patents have proven more pro- 
tective than those for more classical pharmaceuticals. 
Historically, 30--40 new therapeutics of all classes were 
introduced for the first time in 1990, 1991, and 1992. 
Nearly 10% of these introductions were biotechnol- 
ogy products, notably, several IFNs and CSFs, and al- 
glucerase (a modified glucocerebrosidase). Of course, 
with the typical flurry of approvals at the year's end, 
we don't yet know how many new human thera- 
peutics will be introduced for the first time in 1993. 
But, from a biotechnology perspective, some poten- 
tial blockbusters are on the horizon. These include 
IFN]]-lb (introduced into the marketplace this Fall) 
for multiple sclerosis and DNase for cystic fibrosis and 
chronic bronchitis. The setbacks for IL-1 receptor an- 
tagonist (IL-lra) and sepsis mAbs like HA-1A and E5 
are also noteworthy, if not entirely unprecedented. 
pharmacoeconomics worldwide, the combination of 
biotechnological and pharmaceutical technologies and 
strategies should allow key players not only to remain 
strong, but also to enhance their competitive posi- 
tions. Whereas, in the past, solid development skills 
alone enabled pharmaceutical companies to succeed 
profitably, in this decade, both creative research and 
innovative development programs seem the require- 
ment for success. To date, one might conclude that 
the promise of biotechnology has already delivered 
a desirable reality. In 1992, about 10 biotechnology 
products were listed in the top 100 pharmaceutical 
products (Med Ad News, 'The Leading 100 Drags 
Worldwide', May 1993, ppS5). Enzymes like DNase, 
perhaps, will join this meritorious group in the near 
future, and new applications (e.g. multiple sclerosis) 
for IFNs will expand the marketplace for biotechnology 
derived therapeutics. Moreover, with a much smaller 
infrastructure to support, each biotechnology product 
contributes more to the well being of its progenitors 
than an equivalent pharmaceutical. More than ever 
before, biotechnology products can claim their right- 
ful position alongside pharmaceuticals. Surely, the past 
promises of biotechnology are simply a prologue and 
the future realities sublime. Stay tuned! 
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The reality 
Despite the cloud of 'Clintonomics' currently hanging 
over the US pharmaceutical industry, and the gen- 
eral trend toward critically introspective value-based 
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